{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T22:04:08Z","timestamp":1747260248626,"version":"3.40.5"},"reference-count":37,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T00:00:00Z","timestamp":1669248000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011218","name":"Sandoz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011218","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although rituximab is generally well\u2010tolerated, infusion\u2010related reactions (IRRs) are common with the initial dose when administered intravenously according to standard recommendations. To prevent IRRs, premedication and low\u2010speed infusion rates have been recommended. Consequently, intravenous (i.v.) infusion of rituximab can become a labor\u2010intensive process. Rapid i.v. rituximab infusion over 90\u2009min has demonstrated a favorable safety profile for the second and subsequent infusions during the course of therapy. The aim of this study was to investigate the safety and tolerability of 90\u2010min rapid infusion of Sandoz rituximab biosimilar (SDZ\u2010RTX) for patients with CD20+ lymphoma or chronic lymphocytic leukemia (CLL). We retrospectively reviewed all patients with CD20+ lymphoma or CLL who received SDZ\u2010RTX infusions in 90\u2009min from July 2019 to July 2021 at seven Spanish hospitals. The primary end point was the incidence of IRRs. We identified 124 patients and 576 rapid administrations of SDZ\u2010RTX, with an average of five rapid infusions per patient. Most rapid infusions of SDZ\u2010RTX were in combination with CHOP\/CHOP\u2010like therapy (48.4%), followed by SDZ\u2010RTX alone (15.1%), in combination with bendamustine (14.5%), or with other regimens (22%). The 90\u2010min SDZ\u2010RTX infusion schedule was well\u2010tolerated with no grade 3\/4 IRRs. The incidence of any grade IRR during the first rapid infusion was 1% (5 grade 1 IRRs and 1 grade 2 IRR). In conclusion, rapid 90\u2010min i.v. administration of SDZ\u2010RTX for the second and subsequent infusions during the course of therapy is well\u2010tolerated in patients with CD20+ lymphoma or CLL.<\/jats:p>","DOI":"10.1111\/cts.13450","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T05:08:23Z","timestamp":1668661703000},"page":"305-312","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety and tolerability of a 90\u2010minute rapid infusion of Sandoz biosimilar rituximab in B\u2010cell lymphoproliferative disorders in a real\u2010world setting"],"prefix":"10.1111","volume":"16","author":[{"given":"Ana","family":"Munta\u00f1ola","sequence":"first","affiliation":[{"name":"Department of Hematology Hospital Universitari Mutua Terrassa  Terrassa Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Argui\u00f1ano\u2010P\u00e9rez","sequence":"additional","affiliation":[{"name":"Department of Hematology Hospital Universitario de Navarra  Pamplona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"D\u00e1vila","sequence":"additional","affiliation":[{"name":"Department of Hematology Complejo Asistencial de \u00c1vila  \u00c1vila Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia Gonz\u00e1lez","family":"de Villambrosia","sequence":"additional","affiliation":[{"name":"Department of Hematology Hospital Universitario Marqu\u00e9s de Valdecilla\/IDIVAL  Santander Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia","family":"Carpio","sequence":"additional","affiliation":[{"name":"Department of Hematology, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO) Vall d'Hebron University Hospital  Barcelona Spain"},{"name":"Department of Medicine Universitat Aut\u00f2noma de Barcelona  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Jim\u00e9nez\u2010Ubieto","sequence":"additional","affiliation":[{"name":"Department of Hematology Hospital 12 de Octubre  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4652-4825","authenticated-orcid":false,"given":"Antonio","family":"Salar","sequence":"additional","affiliation":[{"name":"Department of Hematology Hospital del Mar  Barcelona Spain"},{"name":"Group of Applied Clinical Research in Hematology Cancer Research Program\u2010IMIM (Hospital del Mar Medical Research Institute)  Barcelona Spain"},{"name":"Pompeu Fabra University  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the GELTAMO (Grupo espa\u00f1ol de linfomas y trasplante de m\u00e9dula \u00f3sea)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,11,24]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2005.05.007"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.6.2188"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.200001"},{"key":"e_1_2_10_5_1","unstructured":"Summary of product characteristics: MabThera. Accessed 22 November 2022. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/mabthera\u2010epar\u2010product\u2010information_en.pdf"},{"issue":"6","key":"e_1_2_10_6_1","doi-asserted-by":"crossref","first-page":"e0157957","DOI":"10.1371\/journal.pone.0157957","article-title":"Time savings with rituximab subcutaneous injection versus rituximab intravenous infusion: a time and motion study in eight countries","volume":"11","author":"Cock E","year":"2016","journal-title":"PLoS One"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2014.914033"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-021-06277-8"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.877135"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1420"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.11124\/jbisrir-2011-69"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2006.00713.x"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2011.000319"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/629283"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-059469"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.2147\/BS.S16120"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-425744"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2016.06.005"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-85563-1"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2019.10.010"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2015.14"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2019.1562905"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2008-0012"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1306648"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1086\/424447"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00010"},{"key":"e_1_2_10_27_1","unstructured":"A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed\/Refractory (R\/R) Follicular Lymphoma or Marginal Zone Lymphoma. Accessed 20 November 2022.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04680052."},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2018891598"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713976"},{"issue":"23","key":"e_1_2_10_30_1","first-page":"2628","article-title":"Venetoclax\u2010rituximab with or without bendamustine vs bendamustine\u2010rituximab in relapsed\/refractory follicular lymphoma","volume":"136","author":"Zinzani PL","year":"2020","journal-title":"Blood"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006578"},{"issue":"3","key":"e_1_2_10_32_1","first-page":"CNS19","article-title":"Rapid infusion rituximab is well tolerated in patients with primary CNS lymphoma. CNS","volume":"7","author":"Modelevsky L","year":"2018","journal-title":"Oncologia"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.170480"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.6547"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220978450"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-010-0583-z"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.2631"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70005-1"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.13450","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cts.13450","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.13450","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T18:00:22Z","timestamp":1692295222000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.13450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,24]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1111\/cts.13450"],"URL":"https:\/\/doi.org\/10.1111\/cts.13450","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"type":"print","value":"1752-8054"},{"type":"electronic","value":"1752-8062"}],"subject":[],"published":{"date-parts":[[2022,11,24]]},"assertion":[{"value":"2022-09-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}